ORIGIN 

Calciphylaxis is a rare, painful disease, with a poor prognosis and no proven treatment options. To date, no randomised controlled trials for calciphylaxis treatments have been completed and there is considerable variation in its clinical management. New data and new treatments for calciphylaxis are urgently needed.

STUDY OVERVIEW

BEAT-Calci is an investigator-initiated, multicentre, international, prospective, adaptive, platform, randomised controlled trial. It has been developed to specifically address the unique barriers to research in this rare disease.

BEAT-Calci aims to establish high-quality evidence on the effect of a range of interventions in patients with kidney failure and newly diagnosed calciphylaxis. The platform design allows multiple treatments, across diverse ‘domains’ of therapeutic care, to be assessed within one trial. This makes discovering the best treatment/s quicker and more reliable.

BEAT-Calci is currently recruiting in Australia and New Zealand, with plans to expand its research into Europe and North America.

EXPERTISE 

The CTC holds significant expertise in nephrology, adaptive methodology, and delivery of international research - all needed to successfully deliver efficient calciphylaxis research. The investigators utilize creative solutions to have; multiple treatments tested at once, intensify treatment in patients with worsening disease, and reduce the time needed to find whether treatments work.

DURATION

Started 2020 - ongoing

COLLABORATORS

Australasian Kidney Trials Network, Waitemata District Health Board (New Zealand), Northern Care Alliance NHS Trust (United Kingdom)

FURTHER READING

Study overview